Inovio Pharmaceuticals Inc (NASDAQ:INO) announced that its DNA vaccine and dMAb antibody for CHIKV can provide full protection against chikungunya. As per the reports, Inovio conducted a study on mice to check the efficacy of its drug and found that it could protect them adequately from chikungunya virus.
Insights of Matter
The findings of this study were published in the latest issue of one of the most prominent publications The Journal of Infectious Diseases’ paper titled “Rapid & long-term immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against Chikungunya virus.” The paper was primarily prepared by Inovio’s research authors and other collaborators.
It’s not the first time when a company has tried to find a cure for CHIKV. Previously, many companies came up with marketed monoclonal antibody and conventional vaccine technologies to get rid of CHIKV, but they couldn’t heal it entirely. On the other hand, the dMAb products and DNA vaccine of Inovio have shown the potential to become a permanent cure for CHIKV. If given attention, they can help thousands of people suffering from this virus all around the globe.
Over the last many years, CHIKV virus has affected millions of people in Asia, Africa, Europe and more than 43 other countries. It was 2013 when it was first found in Americas on Caribbean islands and spreading to other parts, including U.S. With the passage of time, the world has seen an enormous increment in the number of CHIKV cases. There’s an urgent need for an antivirus that can deal with CHIKV before it results in a global outbreak.
Where conventional vaccines take weeks to show their effect, Inovio’s DNA vaccine and the dMAb antibody can start showing their impact within as little as two-three days. The senior management team of the company is delighted to announce this update and hopes to continue this momentum in the upcoming trials as well.
